Blueprint Presents Proof-of-Concept Data of BLU-945 in P-I/II (SYMPHONY) Trial for EGFR-Mutant Non-Small Cell Lung Cancer at AACR 2022
- The P-I/II (SYMPHONY) trial evaluates BLU-945 in patients with EGFR-mutant NSCLC. The results showed early evidence of safety & clinical activity consistent with preclinical data
- The P-I (SYMPHONY) trial showed dose-dependent reductions in ctDNA & radiographic tumor including PR & PK results showed BLU-945 exposures at higher doses associated with broad EGFR mutation coverage, were well-tolerated with no significant AEs
- The company initiates (SYMPHONY) trial of BLU-945 + osimertinib in patients with 2L or later EGFR-mutant NSCLC. Under the clinical trial supply agreement with AstraZeneca, Blueprint will evaluate BLU-945 & BLU-701 in combination with osimertinib in (SYMPHONY) & (HARMONY) trials
Ref: Blueprint Medicine | Image: Linkedin
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.